Repligen (RGEN) – Research Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Repligen (NASDAQ: RGEN):

• 7/7/2026 – Repligen was upgraded by Citigroup Inc. to “buy”.
• 7/7/2026 – Repligen was upgraded by Benchmark Co. from “hold” to “buy”. They now have a $185.00 price target on the stock.
• 7/6/2026 – Repligen had its “outperform” rating reaffirmed by Evercore Inc. They now have a $160.00 price target on the stock.
• 6/26/2026 – Repligen was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 6/3/2026 – Repligen had its price target lowered by HSBC Holdings plc from $170.00 to $150.00. They now have a “buy” rating on the stock.
• 6/2/2026 – Repligen is now covered by Wolfe Research. They set an “outperform” rating and a $145.00 price target on the stock.
• 6/1/2026 – Repligen was upgraded by Wolfe Research to “strong-buy”.

Insider Transactions at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. The trade was a 3.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.60% of the company’s stock.

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.